Analysts See $-0.32 EPS for Aldeyra Therapeutics, Inc. (ALDX)

March 18, 2018 - By Ellis Scott

 Analysts See $ 0.32 EPS for Aldeyra Therapeutics, Inc. (ALDX)
Investors sentiment increased to 3.13 in 2017 Q3. Its up 1.46, from 1.67 in 2017Q2. It is positive, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported.
Deutsche Commercial Bank Ag holds 8,000 shares. Barclays Public Ltd Limited Liability Company holds 0% or 3,400 shares. State Street Corporation holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 18,500 shares. Woodstock Corp invested in 0.07% or 48,393 shares. Knoll Lp has 124,096 shares for 0.76% of their portfolio. Perceptive Advsrs Ltd Liability Corp accumulated 3.09M shares or 0.85% of the stock. Moreover, Blackrock Inc has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Jane Street Gru Ltd Liability Com owns 10,961 shares. Renaissance Technologies Ltd Company has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Ellington Grp Ltd Liability Company reported 23,300 shares or 0.03% of all its holdings. Drw Secs Limited Liability Corp owns 0.03% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 12,000 shares. Royal Bankshares Of Canada reported 9 shares or 0% of all its holdings. Ardsley Advisory holds 0.04% or 39,552 shares in its portfolio. Tower Research Capital Lc (Trc) owns 3,183 shares. Weiss Multi reported 0.01% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.86% or $0.25 during the last trading session, reaching $8.5. About 112,808 shares traded or 11.01% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 18.94% since March 18, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. H.C. Wainwright maintained Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Wednesday, August 9 with “Buy” rating. Cowen & Co initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Tuesday, September 8 with “Outperform” rating. The stock has “Buy” rating by Canaccord Genuity on Wednesday, September 13. The firm has “Buy” rating by H.C. Wainwright given on Thursday, June 15. On Thursday, September 14 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) earned “Buy” rating by H.C. Wainwright on Monday, September 26. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 1. The rating was maintained by Canaccord Genuity on Wednesday, June 14 with “Buy”. As per Wednesday, August 9, the company rating was maintained by Cowen & Co. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, November 9.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $162.50 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.